Takeda: Kidney Failure, Chronic trials

The registry lists 14 Kidney Failure, Chronic studies with Takeda as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 2Phase 3 5Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal DiseaseCompletedNCT02512068Phase 3Results posted
• Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder TherapyCompletedNCT01130831Results posted
• Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy AdultsCompletedNCT00880750Phase 1Results posted
• Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult VolunteersCompletedNCT00875017Phase 1Results posted
• Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.CompletedNCT00752609Phase 2Results posted
• DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)TerminatedNCT00664066Results posted
• Dynepo Long-Term Safety StudyTerminatedNCT00514813Phase 4Results posted
• Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney DiseaseCompletedNCT00314795Phase 2Results posted
• Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)CompletedNCT00567723
• Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal DiseaseCompletedNCT00160121Phase 4
• Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving DialysisCompletedNCT00151931Phase 3
• Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal DiseaseCompletedNCT00151918Phase 3
• Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their BloodCompletedNCT00150566Phase 3
• A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.CompletedNCT00150540Phase 3